Mubadala Acquires 100% of Pan-African KELIX Bio
The transaction is pending customary regulatory approvals.
Abu Dhabi-based sovereign investor Mubadala Investment Company PJSC (Mubadala) has finalized a deal to acquire 100% of the pan-African biopharmaceuticals platform KELIX bio for an undisclosed sum.
Established in November 2020, KELIX bio has acquired manufacturing entities across key markets like India, Egypt, Malta, and Morocco. Their portfolio encompasses a wide range of oral and injectable medications targeting various therapeutic areas such as diabetes, oncology, cardiology, and central nervous system disorders.
With a pressing need for pharmaceuticals due to prevalent non-communicable diseases like cardiovascular disorders, cancer, and diabetes, the UAE has historically relied on imports. Mubadala's acquisition strategy aligns with its vision to bolster the nation's healthcare infrastructure, reduce dependency on imports, and foster innovation in pharmaceutical manufacturing.
Prior to Mubadala's acquisition, KELIX bio was held by a consortium of investors, including Development Partners International (DPI), British International Investment (BII), and the European Bank for Reconstruction and Development (EBRD).
The transaction is pending customary regulatory approvals.
